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Abstract
Focal nodular hyperplasia (FNH) is a benign condition 
that affects normal liver with low prevalence. Recently, 
the extensive use of oxaliplatin to treat patients with 
colorectal cancer has been reported to be associated 
with the development of different liver injuries, as well 
as focal liver lesions. The present work describes two 
patients with multiple bilateral focal liver lesions mis-
diagnosed as colorectal liver metastases, and treated 
with liver resection. The first patient had up to 15 small 
bilateral focal liver lesions, with magnetic resonance 
imaging consistent with colorectal liver metastases 
(CLM), and fluorodeoxyglucose (FDG)-positron emis-
sion tomography (PET) negative. The second patient 
had up to 5 small focal liver lesions, with computed 
tomography consistent with CLM, and FDG-PET nega-
tive. They had parenchyma sparing liver surgery, with 
uneventful postoperative course. At the histology the 
diagnosis was multiple FNHs. The risks of oxaliplatin-
based chemotherapy regimens in development of liver 
injuries, such as FNH, should not be further denied. 
The value of the modern multidisciplinary management 
of patients with colorectal cancer relies also on the 
precise estimation of the risk/benefit for each patient. 
© 2013 Baishideng. All rights reserved.
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Core tip: This report describes two interesting cases of 
patients who developed multiple focal nodular hyper-
plasias during oxaliplatin-based therapy for colorectal 
cancer. Such multiple bilateral focal liver lesions were 
misdiagnosed as colorectal liver metastases, and treat-
ed with liver resection. A review of the cases revealed 
that in both cases the fluorodeoxyglucose-positron 
emission tomography was negative. A brief review of 
the literature together with the authors’ comments is 
included.
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INTRODUCTION
Focal nodular hyperplasia (FNH) is a benign condition 
that affects normal liver with prevalence up to 2.6% in 
autopsy studies[1,2]. Most of  the patients are asymptom-
atic, while few of  them may develop portal hyperten-
sion[3,4]. The physiopathology of  FNH remains unknown, 
but non-specific chronic distortion of  the intrahepatic 
blood flow has been considered a potential cause[5]. Re-
cently, the extensive use of  oxaliplatin to treat patients 
with colorectal cancer has been reported to be associated 
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with the development of  different liver injuries[5,6]. The 
present work describes two patients with multiple bilat-
eral focal liver lesions misdiagnosed as colorectal liver 
metastases (CLM), and treated with liver resection.
CASE REPORT
Case 1
A 53-year-old woman presented at the liver surgery unit 
because of  multiple focal liver lesions. In December 
2007 in another institution after a preoperative staging 
comprehensive of  an abdominal computed tomography 
(CT), which resulted negative for liver lesions, the patient 
had laparoscopic right colectomy because of  colonic 
adenocarcinoma pathologically staged as pT3N2M0-G2. 
Then, she had 8 courses of  systemic chemotherapy 
with FOLFOX regimen (oxaliplatin, leucovorin, and 
fluorouracil) followed by 4 courses of  De Gramont regi-
men (fluorouracil and folinic acid). The modification of  
the chemotherapy regimen was due to oxaliplatin side 
effects, such as peripheral neuropathy, and thrombo-
cytopenia. Then the follow-up, based on quarterly CT, 
was regular and negative till January 2010, when she 
developed up to 15 bilateral focal liver lesions. She was 
than referred to our institution where she underwent a 
diagnostic work-up comprehensive of  abdominal mag-
netic resonance imaging (MRI) and fluorodeoxyglucose 
(FDG)-positron emission tomography (PET) scan. MRI 
was consistent with the diagnosis of  CLM, while FDG-
PET was negative (Figure 1). Both the carcinoembryonic 
antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) 
serum values were normal. The CEA was elevated be-
fore the colonic resection. Based on our weekly multi-
disciplinary meeting the patient was candidate to surgical 
resection. Therefore, after 14 mo from the end of  the 
adjuvant chemotherapy, in March 2010 she had multiple 
ultrasound-guided liver resections for the removal of  
all 15 lesions. The postoperative course was uneventful. 
At gross inspection the lesions sized between 0.5 and 
2 cm and were characterized by well-defined margins, 
lobulated appearance, and a central scar (Figure 2A). 
At histology the lesions were characterized by several 
fibrous septa highlighted by special stains (Figure 2B, 
Masson staining), and they showed a typical patter at 
glutamine synthetase immunostaining (Figure 2C). Yet, 
at higher magnification they contained several dystrophic 
vessels (Figure 2D). All these findings were in keeping 
with a diagnosis of  multiple FNH without any evidence 
of  malignant cells. She did not receive postoperative 
chemotherapy. After 32 mo the patient is alive, and free 
of  tumoral recurrence. However, this patient developed 
4 new small liver lesions consistent with multiple FNHs, 
which are stable after 13 mo of  follow-up.
Case 2
A 56-year-old man presented at the liver surgery unit be-
cause of  multiple focal liver lesions. In July 2008 after a 
preoperative staging comprehensive of  an abdominal CT, 
which resulted negative for liver lesions, the patient had 
laparoscopic left colectomy because of  colonic adeno-
Donadon M et al . Multiple FNH caused by oxaliplatin-based chemotherapy
341 June 27, 2013|Volume 5|Issue 6|WJH|www.wjgnet.com
B
A
Figure 1  Radiological imaging of case 1. A: The abdominal contrast-enhanced magnetic resonance imaging showed multiple bilateral focal liver lesions (arrows); B: 
The fluorodeoxyglucose-positron emission tomography scan did not show any pathological uptake of the trace. 
carcinoma pathologically staged as pT3N1M0-G2. Then, 
the patient had 12 courses of  systemic chemotherapy 
with FOLFOX regimen. The subsequent follow-up was 
regular and negative till March 2011, when he developed 
up to 5 bilateral focal liver lesions and was referred to 
out institution where he had abdominal CT and FDG-
PET scan. CT was consistent with the diagnosis of  CLM, 
while FDG-PET was negative (Figure 3). Both the CEA 
and CA19-9 serum values were normal, and they were 
within the normal range even before the colonic resec-
tion. Based on our weekly multidisciplinary meeting the 
patient was candidate to surgical resection, and in June 
2011, 16 mo the end of  adjuvant chemotherapy, he had 
multiple ultrasound-guided liver resections for the remov-
al of  all 5 lesions. The postoperative course was unevent-
ful. Similarly to the previous patient, at gross inspection 
the larger lesion was 2 cm in diameter. They were charac-
terized by well-defined margins, and the histology review 
showed some typical findings consistent with the diagno-
sis of  multiple FNHs. He did not receive postoperative 
chemotherapy. After 20 mo the patient is alive and free 
of  recurrence.
DISCUSSION
The presented cases showed two patients affected by 
colorectal cancer with multiple FNHs potentially in-
ducedby oxaliplatin-based chemotherapy. Both of  them 
had no history of  chronic liver disease, and the chrono-
logical correlation between the chemotherapy, its dura-
tion, and the appearance of  the liver lesions suggests a 
cause-effect association. 
There is a burgeoning use of  preoperative chemother-
apy in patients with CLM, and a corresponding burgeon-
ing literature reporting non-tumoral liver lesions induced 
by different chemotherapy regimens[6]. Some direct corre-
lations between chemotherapy agents, specific liver toxici-
ty and postoperative morbidity have been also reported[7,8]. 
In particular, the development of  FNH during oxaliplatin-
based systemic chemotherapy has been reported up to 
15% of  the patients treated with preoperative chemother-
apy[9]. Based on a recent review on such topic the damages 
associated with oxaliplatin-based chemotherapy are com-
plex and heterogeneous. Both erythrocyte extravasation 
and hepatocytic plate disruption have been reported being 
signs of  sinusoidal wall rupture[5,10]. However, the patho-
genesis of  FNH remains unclear. Changes in intrahepatic 
blood flow are supposed to be the primary cause. Such 
changes may be due to portal vein injuries at the level of  
the sinusoids, and the resulting portal hypertension plays 
an important role. The natural history of  FNH remains 
unknown, too. Few spontaneous regressions after the sus-
pension of  the chemotherapy have been reported as well 
as some protective effects of  bevacizumab on the devel-
opment of  this toxicity[5,11,12].
From the clinical standpoint their proper diagnosis is 
a delicate matter, since they occur in oncological patients 
with generally well-documented, and extensive negative 
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Figure 2  Histology of case 1. A: The gross inspection of the specimen showed lesions sized between 0.5 and 2 cm, with well-defined margins, and a central scar; B, C: 
At microscopy the lesions were characterized by several fibrous septa highlighted by special stains (Masson staining), and they showed a typical patter at glutamine 
synthetase immunostaining; D: At higher magnification they contained several dystrophic vessels.
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imaging. In our two patients to these consideration the 
multinodular pattern has further biased the diagnostic 
conclusion. Indeed, only Hubert et al[11] previously re-
ported two cases of  multiple FNHs occurred in similar 
circumstances while other authors described patients with 
single lesions[5,6,9]. Our experience is conveying a further 
peculiarity, which could be useful for further discussion 
and experiences in this sense. Indeed, to our knowledge 
no previous studies on the use of  FDG-PET in such 
specific clinical setting have been reported. Even if  no 
conclusions can be drawn based on two cases, and con-
sidering also the tendency of  lower accuracy of  FDG-
PET after chemotherapy[13], a potential value of  such im-
aging modality should be further investigated, and taken 
into account during the workup in such circumstances.
In conclusion, an increasing proportion of  patients 
with CLM nowadays receive oxaliplatin-based chemo-
therapy, including postoperative treatment after stage Ⅲ 
colon cancer, induction therapy in patients with extensive 
metastases, and perioperative treatment in patients with 
resectable metastases. The risks of  such chemotherapy 
regimens in development of  FNHs, as well as of  other 
forms of  liver injuries, should not be further denied. The 
value of  the modern multidisciplinary management of  
patients with colorectal cancer relies also on the precise 
estimation of  the risk/benefit for each patient.
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